Product
Alveavax-v1.2
1 clinical trial
1 indication
Indication
COVID-19Clinical trial
A Phase 1 Open-label, Active-controlled, Randomized Dose-finding Study to Evaluate Safety, Tolerability, and Immunogenicity of Intradermal and Subcutaneous Application of the Plasmid DNA SARS-CoV-2 Omicron BA.2 Vaccine Alveavax-v1.2 in Primary Ad26.COV2.S Vaccinated Healthy IndividualsStatus: Completed, Estimated PCD: 2023-03-02